Skip to content

The role of dopamine and oxytocin in individual and social performance monitoring

The role of dopamine and oxytocin in individual and social performance monitoring - Dopamine, oxytocin and performance monitoring

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50126
Enrollment
30
Registered
2019-03-07
Start date
2020-01-30
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitieve prestatie cognitive performance (performance monitoring)

Interventions

Oxytocin, L-DOPA, or placebo will be administered in randomized order over the course of three sessions. After administration, resting state and structural scans will be made and participants will p

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy, right-handed males between age 18 and 35 with no history of neurological disorder/disease, no substantial psychiatric history, and no counter-indications to MRI will be included in this study.

Exclusion criteria

Exclusion criteria: Participants should meet none of the following exclusion criteria: - History of medication or drugs within 1 month prior to the start of treatment with trial medication with the exception of occasional use of paracetamol. - Previous experience of allergic reaction upon administration of a drug. - Use of hayfever medication - Medical or surgical history that in the investigator*s view may significantly affect the outcome of the trial; such as severe visual impairment - Significant history of head trauma, premature birth, or learning disabilities. - Heart arrhythmia (including pacemaker/ICD), glaucoma, hypertension. - Clinically significant history of abnormal cardiovascular, endocrine, psychiatric, neurological or hematological disease. - Febrile illness within 3 days before the first dose - Fever or cold within 2 days before the experiment - Participation in another drug study within 3 months preceding participation in the current study. - Intake of more than 3 units of alcohol / day - Smoking more than 5 cigarettes / day - Inability to understand the nature and extent of the trial and the procedures required.

Design outcomes

Primary

MeasureTime frame
Brain activation during the various tasks and scans (resting state scans, Cannonball task, Prosocial Probabilistic Learning task, Working Memory task) across the different (pharmacological) conditions.

Secondary

MeasureTime frame
Behavioural outcomes such as accuracy and self-reported responsibility levels in the different tasks and scans (resting state scans, Cannonball task, Prosocial Probabilistic Learning task, Working Memory task) across the different (pharmacological) conditions.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)